Zobrazeno 1 - 10
of 151
pro vyhledávání: '"PAOLO MAIONE"'
Publikováno v:
Current Oncology, Vol 31, Iss 2, Pp 987-997 (2024)
Patients with radically resected stage II and III NSCLC are exposed to a high risk of disease recurrence. Thus, adjuvant cisplatin-based chemotherapy is routinely offered to this patient population, although it results in an absolute increase in 5-ye
Externí odkaz:
https://doaj.org/article/dc11de8890194c9da70cc7a767b4c9c4
Autor:
Piera Gargiulo, Laura Arenare, Cesare Gridelli, Alessandro Morabito, Fortunato Ciardiello, Vittorio Gebbia, Paolo Maione, Alessia Spagnuolo, Giuliano Palumbo, Giovanna Esposito, Carminia Maria Della Corte, Floriana Morgillo, Gianfranco Mancuso, Raimondo Di Liello, Adriano Gravina, Clorinda Schettino, Massimo Di Maio, Ciro Gallo, Francesco Perrone, Maria Carmela Piccirillo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Chemotherapy-induced neutropenia (CIN) has been demonstrated to be a prognostic factor in several cancer conditions. We previously found a significant prognostic value of CIN on overall survival (OS), in a pooled dataset of patien
Externí odkaz:
https://doaj.org/article/a4ff3976bddf475882f1ba7ca7d1a374
Autor:
Pasquale Pisapia, Antonino Iaccarino, Caterina De Luca, Gennaro Acanfora, Claudio Bellevicine, Roberto Bianco, Bruno Daniele, Luisa Ciampi, Marco De Felice, Teresa Fabozzi, Luigi Formisano, Pasqualina Giordano, Cesare Gridelli, Giovanni Pietro Ianniello, Annamaria Libroia, Paolo Maione, Mariantonia Nacchio, Fabio Pagni, Giovanna Palmieri, Francesco Pepe, Gianluca Russo, Maria Salatiello, Antonio Santaniello, Rachele Scamarcio, Davide Seminati, Michele Troia, Giancarlo Troncone, Elena Vigliar, Umberto Malapelle
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8541 (2022)
Background: Immune-checkpoint inhibitors (ICIs) have increased and improved the treatment options for patients with non-oncogene-addicted advanced stage non-small cell lung cancer (NSCLC). However, the role of ICIs in oncogene-addicted advanced stage
Externí odkaz:
https://doaj.org/article/8ce22fcb0a8140418931b8965a5455f4
Autor:
Paolo Maione, Paola Claudia Sacco, Assunta Sgambato, Francesca Casaluce, Antonio Rossi, Cesare Gridelli
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 7 (2015)
The discovery that a number of aberrant tumorigenic processes and signal transduction pathways are mediated by druggable protein kinases has led to a revolutionary change in nonsmall cell lung cancer (NSCLC) treatment. Epidermal growth factor recepto
Externí odkaz:
https://doaj.org/article/94fdebc8d06643ebb0af4c35d0a155b0
Autor:
Paolo Maione, Antonio Rossi, Paola Claudia Sacco, Maria Anna Bareschino, Clorinda Schettino, Marianna Luciana Ferrara, Marzia Falanga, Rita Ambrosio, Cesare Gridelli
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 2 (2010)
More than 40% of cases of all lung cancers are diagnosed in patients over the age of 70 years. Elderly patients have more comorbidities and tend to be less tolerant to toxic medical treatments than their younger counterparts. Thus, clinical data obta
Externí odkaz:
https://doaj.org/article/c9df527611e745cdbdacab043b2ac4dc
Autor:
Clorinda Schettino, Maria Anna Bareschino, Antonio Rossi, Paolo Maione, Vincenzo Castaldo, Nicole Mazzeo, Paola Claudia Sacco, Marianna Luciana Ferrara, Giovanni Palazzolo, Fortunato Ciardiello, Cesare Gridelli
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 1 (2009)
Improving outcomes for early-stage non-small cell lung cancer (NSCLC) is a major research area considering that a significant percentage of such patients develop recurrent disease within 5 years of complete lung resection. Adjuvant chemotherapy prolo
Externí odkaz:
https://doaj.org/article/0a672a3bbcb74d109d19f2c65474c5ff
Autor:
FRANCESCO JACOPO ROMANO, RICCARDO RONGA, FRANCESCA AMBROSIO, DARIO ARUNDINE, VITO LONGO, DOMENICO GALETTA, CESARE GRIDELLI, PAOLO MAIONE, VALENTINA PALMA, VINCENZO DAMIANO, ANTONIO VERDE, ILARIA GIACOBBE, MARIA ROSARIA AUGURIO, GENNARO IENGO, MASSIMILIANO CHETTA, MARINA TARSITANO, SEVERO CAMPIONE, GIUSEPPE FAILLA, ANTONIO RAUCCI, FERDINANDO RICCARDI
Publikováno v:
Cancer Diagn Progn
Background/Aim: Lung cancer is one of the most common malignant neoplastic diseases and by far the leading cause of cancer death worldwide. Recently, immune checkpoint inhibitors (ICIs) have received increasing attention for playing a crucial role in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2d898c524d619bebe4c41b1a93261f
https://europepmc.org/articles/PMC9801444/
https://europepmc.org/articles/PMC9801444/
Autor:
Floriana Morgillo, Giovanna Esposito, Gianfranco Mancuso, Francesco Perrone, Fortunato Ciardiello, Maria Carmela Piccirillo, Paolo Maione, Clorinda Schettino, Cesare Gridelli, Raimondo Di Liello, Piera Gargiulo, Vittorio Gebbia, Giuliano Palumbo, Massimo Di Maio, Adriano Gravina, Alessia Spagnuolo, Laura Arenare, Alessandro Morabito, Carminia Maria Della Corte, Ciro Gallo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
BMC Cancer
Background Chemotherapy-induced neutropenia (CIN) has been demonstrated to be a prognostic factor in several cancer conditions. We previously found a significant prognostic value of CIN on overall survival (OS), in a pooled dataset of patients with a
Publikováno v:
Transl Lung Cancer Res
BACKGROUND AND OBJECTIVE: The genetic nature of cancer provides the rationale to support the need for molecular diagnosis and patient selection for individualised antineoplastic treatments that are the best in both tolerability and efficacy for each
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::886caa11e637b10c115563b93ddc45b6
https://europepmc.org/articles/PMC9271439/
https://europepmc.org/articles/PMC9271439/
Publikováno v:
Expert review of anticancer therapy. 22(2)
Chemo-immunotherapy combinations have revolutionized our treatment algorithm with respect to naïve advanced NSCLC; however, given the great number of developed and approved combinations, the question arises as to which combinations provide the best